The Medical Letter on Drugs and Therapeutics
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
Article code: 1625b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.